A Guide to Intellectual Property Protection in Biotechnology and Genetics

Biotechnology and genetics require huge investments for research but the return on investment will be delayed. Intellectual Property (IP) can help the industry recover the funds spent on research and development (R&D) in the biotech and genetics industry. 

Proper IP protection is essential for researchers in this field to come up with critical innovations that are useful for people’s health. Failing to protect IP in the biotechnology and genetics field will lead to competitors replicating innovations. It will be hard for you to stop such infringers if you fail to register your IP. 

This article discusses the key tenets of IP in biotechnology and genetics such as identification of IP assets, various strategies and their pros and cons, and steps involved in your journey from conception to commercialization. We can provide you with some useful tips to save your innovations from infringement: 

Understanding IP in Biotechnology and Genetics

IP can be termed the lifeblood of the biotech and genetic industry due to the humongous R&D investment involved. Various aspects of innovations in biotechnology and genetics can be safeguarded through Patents, Trade Secrets, Trademarks, Copyrights, and Regulatory Exclusivity. 

Patents

Once a company acquires a patent, specifics of its technology enter the public domain. It inspires other companies to create their own unique innovations. Patent licenses play a key role in new research and inventions in biotechnology and genetics and hence contribute immensely to human health and well-being. 

Trade Secrets

Confidential information can be protected through trade secrets. The information can be processes, formulas, patterns etc. Trade secrets can be recorded if it is,

• Kept secret
•  Has commercial value as it is kept secret
• Those responsible for controlling the information have taken reasonable measures to keep it confidential.

Any information meeting these criteria can be protected as trade secrets in biotechnology and genetics. It can be manufacturing processes, research methods, and formulas.

While patent information enters the public domain, trade secrets remain confidential. If trade secrets are leaked into the public domain, you can file a lawsuit against the culprits. However, the damage can be undone as the secret is no longer a secret. Typically, the information can be leaked by employees, developers, suppliers, collaborators, or any interested parties. Companies can use disclosure agreements to stop the theft of trade secrets. 

Trademarks

Trademarks protect brand names, logos, and slogans used to distinguish products in the marketplace. In biotechnology, trademarks are useful for protecting product and company names and are used to brand products like pharmaceuticals, genetically engineered crops, branding/marketing terms, research tools and names for products, equipment, services and more. They are often overlooked, despite having real value later on when marketing becomes essential.

Trademark protection can last indefinitely as long as the mark is renewed and continues to be used in commerce.

Copyrights

Although it may seem unlikely, copyrighted works and copyright law are significant considerations in biotechnology. DNA sequences, in particular, have sparked debates regarding their eligibility for copyright protection as works of authorship. Although, it appears that the Copyright Office does not agree that DNA sequences are copyrightable.

They also protect original works of authorship like software, databases, technical manuals, and scientific publications. While limited to the expression of ideas rather than the ideas themselves, copyrights can still be useful in the biotech industry to protect materials such as educational content, digital media, bioinformatics software, genomic databases, and other informational tools.

Copyright protection lasts for the life of the author plus 70 years.

Regulatory Exclusivity

Regulatory exclusivity refers to a period of marketing exclusivity granted by regulatory agencies upon approval of a new drug, biologic, or medical device. In the US, the FDA may grant 3 to 7 years of exclusivity to prevent competitors from relying on the data in your application. The EU has similar provisions that grant 8 to 11 years of exclusivity. Regulatory exclusivity provides strong protection but only for a limited time.